| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Tubulin alpha-1B chain;Alpha-tubulin ubiquitous;Tubulin K-alpha-1;Tubulin alpha-ubiquitous chain;TUBA1B; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human ATP4B |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-ATP4B antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone 26A11; isotype IgG; reactivity: Human. Reported application contexts include WB (as provided in the source record). Boster Bio Anti-ATP4B Rabbit Monoclonal Antibody catalog # M08719. Tested in WB application. This antibody reacts with Human.
Key elements and design rationale
- Target: ATP4B (Tubulin alpha-1B chain).
- Antibody format: Monoclonal; clone 26A11; isotype IgG.
- Host: Rabbit.
- Species reactivity: Human (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
ATP4B (protein: T-cell surface glycoprotein CD3 zeta chain) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. Reported cellular localization context: Cytoplasm, cytoskeleton. Tissue expression notes (as provided): Expressed at highest levels in heart, followed by liver and kidney. .
Research relevance and current trends
- Research context keywords from the source record include: Cell Type Marker,Neuroscience.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
Workflow ideas (metafield): Validate ATP4B antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect ATP4B expression by Western blot in cell or tissue lysates, Compare relative ATP4B levels across experimental conditions (dose/time-course) using antibody-based readouts
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 55 kDa; calculated MW: 50152 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 55 kDa
- Cellular localization (provided): Cytoplasm, cytoskeleton.
- Tissue details (provided): Expressed at highest levels in heart, followed by liver and kidney. .
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
